CEO: Iain Dukes
Headquarters: Dover, Deleware
URL: www.lomondther.com
October 2024
APO Financing: $44,000,000

Lomond Therapeutics is a biopharmaceutical company co-founded by OrbiMed, Torrey Pines Investment and Dr. John C. Byrd, focused on the discovery and development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic cancers. The company is utilizing a proprietary hybrid AI platform (Expert Systems Inc.), leveraging its key partners’ proprietary data, chem-bio platforms, knowledge, and expertise to choose highly valuable molecular mechanisms of pathology; to precisely design and accelerate the execution of discovery and development of best-in-class and first-in-class therapies. Lomond Therapeutics’ goal is to utilize its capabilities and platform to become a leader in developing novel breakthrough medicines to maximize the clinical benefit when treating hematologic malignancies.